Castle Biosciences, Inc. Common Stock (CSTL) is a publicly traded Healthcare sector company. As of October 21, 2026, CSTL trades at $34.39 with a market cap of $1.01B and a P/E ratio of -52.84. CSTL moved +3.74% today. Year to date, CSTL is -10.82%; over the trailing twelve months it is +46.88%. Its 52-week range spans $14.59 to $44.28. Analyst consensus is strong buy with an average price target of $45.40. Rallies surfaces CSTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Castle Biosciences study links low-risk DecisionDx-Melanoma results to 4.4% SLN positivity and 99.6% five-year RFS without SLNB: Castle Biosciences said a prospective study linked low-risk DecisionDx-Melanoma results to 4.4% sentinel lymph node positivity and 99.6% five-year recurrence-free survival without biopsy. The company will present the data at EADV 2026 on Oct. 1 in Vienna.
| Metric | Value |
|---|---|
| Price | $34.39 |
| Market Cap | $1.01B |
| P/E Ratio | -52.84 |
| EPS | $-0.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.28 |
| 52-Week Low | $14.59 |
| Volume | 278.28K |
| Avg Volume | 0 |
| Revenue (TTM) | $357.28M |
| Net Income | $-19.41M |
| Gross Margin | 77.26% |
5 analysts cover CSTL: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.40.